Document Detail

Erythropoietin: a paradigm for the development of practice guidelines.
MedLine Citation:
PMID:  11722976     Owner:  NLM     Status:  MEDLINE    
Erythropoietin (EPO) is an endogenous hormone produced in the kidney that regulates red blood cell production within the body. Since the cloning and first clinical introduction of recombinant erythropoietin (epoetin) in the late 1980s indications and usage of epoetin have expanded significantly. It is estimated that as many as one third of patients with substantial anemia (hemoglobin less than 10.0 g/dL) resulting from chemotherapy for cancer are treated with epoetin. Though use of epoetin may avoid the inconvenience and infectious risk of blood transfusions, it is expensive and its benefit in some clinical scenarios has been modest. Like many new technologies, strong evidence suggesting situations where the benefit is high has lagged behind its adoption by patients and practitioners. As well, epoetin is expensive and third party payers do not always reimburse it. Research suggests there is considerable variation in epoetin usage in practice. To provide guidance to hematology/oncology specialists regarding use of epoetin, the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) proposed that the Agency for Healthcare Research and Quality (AHRQ) fund an evidence review by one of the Evidence-based Practice Centers (EPC) that would be used to develop evidence-based guidelines for members of the society. This review highlights principles of evidence-based medicine, distills and appraises the evidence in the published literature that supports the use of epoetin, and presents evidence-based recommendations for use of epoetin in situations where benefit is substantiated by high-quality studies. As well, this review addresses some of the difficulties of performing clinical research in this area, provocative research findings that will require further study, and suggestions regarding epoetin in those areas where further strong evidence has yet to be developed.
J D Rizzo; J Seidenfeld; M Piper; N Aronson; A Lichtin; T J Littlewood
Related Documents :
22708596 - Neonatal seizures: controversies and challenges in translating new therapies from the l...
21039616 - Debating the legitimacy of a contested environmental illness: a case study of multiple ...
20414476 - Toward an integration of social and biological research.
20500776 - Evidence-based practice in healthcare: an exploratory cross-discipline comparison of en...
15016246 - Addressing the "risk environment" for injection drug users: the mysterious case of the ...
25025076 - Biomedical properties of a natural dietary plant metabolite, zerumbone, in cancer thera...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program     Volume:  -     ISSN:  1520-4391     ISO Abbreviation:  Hematology Am Soc Hematol Educ Program     Publication Date:  2001  
Date Detail:
Created Date:  2001-11-27     Completed Date:  2002-07-17     Revised Date:  2008-02-12    
Medline Journal Info:
Nlm Unique ID:  100890099     Medline TA:  Hematology Am Soc Hematol Educ Program     Country:  United States    
Other Details:
Languages:  eng     Pagination:  10-30     Citation Subset:  IM    
IBMTR/ABMTR, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee WI 53226-4801, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / drug therapy,  etiology
Controlled Clinical Trials as Topic
Erythropoietin / therapeutic use*
Evidence-Based Medicine*
Neoplasms / complications,  drug therapy
Practice Guidelines as Topic
Recombinant Proteins / therapeutic use
Treatment Outcome
United States
United States Agency for Healthcare Research and Quality
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling.
Next Document:  Sickle cell and the brain.